UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/593,868	08/26/2008	Alex Haahr Gouliaev	FRANCH4B	4401	
	E 300 HINGTON, DC 20001-5303 ART UNIT PAPER NUMBER				
624 NINTH STREET, NW SUITE 300 WASHINGTON, DC 20001-5303			WOOLWINE, SAMUEL C		
			ART UNIT	PAPER NUMBER	
			1637		
			MAIL DATE	DELIVERY MODE	
			01/15/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

DATE MAILED:

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
10593868	8/26/2008	GOULIAEV ET AL.	FRANCH4B	
		EXAMINER		
BROWDY AND NEIM 624 NINTH STREET,	*	SAMUEL C. WOOLWINE		
SUITE 300 WASHINGTON, DC 20001-5303			ART UNIT	PAPER
			1637	20091229

Please find below and/or attached an Office communication concerning this application or

Commissioner for Patents

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Notice of Allowance Mailed

proceeding.

This application has been accorded an Allowance Date and is being prepared for issuance. The application, however, is incomplete for the reasons below.

The specification has been found defective for the following reason: the illustrations on pages 41, 42 and 49 (page 49: the illustration of the "BB1", "BB2" and "CPN") of the specification as filed do not come within the exceptions of 37 CFR 1.58(a). Please furnish drawings per 37 CFR 1.81, delete the illustrations from the specification and amend text references as necessary (including "Brief Description of the Drawings" for any new drawings submitted). Alternatively Applicant may simply delete the illustrations and any references thereto from the specification.

In addition, the specification does not comply with 37 CFR 1.821(d): "Where the description or claims of a patent application discuss a sequence that is set forth in the "Sequence Listing" in accordance with paragraph (c) of this section, reference must be made to the sequence by use of the sequence identifier, preceded by "SEQ ID NO:" in the text of the description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application." It is noted that nucleotide sequences appearing on pages 45, 46, 49 and 50 of the specification are not identified by SEQ ID NOs. Please amend the specification accordingly.

/Samuel Woolwine/ Examiner, Art Unit 1637